The Pharmacy Times® Breast Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancers that occur in the breast, including invasive ductal carcinoma, invasive lobular carcinoma, and less common forms of the disease.
July 2nd 2025
Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.
FDA Approves HER2+ Breast Cancer Therapy
December 21st 2017Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with trastuzumab and chemotherapy as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.
Read More